IFF (IFF) Q4 2025 earnings review
Core Strengthens, Food Ingredients Put Up for Sale
IFF delivered on its full-year commitments, but the headline story is the divergence within the portfolio. While Taste and Health & Biosciences (H&B) surged with double-digit EBITDA growth in Q4, Food Ingredients became a significant drag, shrinking in both sales (-4%) and profit (-11%). Management has officially launched a sale process for Food Ingredients, marking the final step in unwinding the complexity of the past few years. With net debt down to 2.6x EBITDA, the balance sheet is repaired; now the focus shifts to shedding the dead weight and driving growth in the core.
🐂 Bull Case
The official launch of the Food Ingredients sale process is the catalyst investors have been waiting for. Divesting this dragging segment will leave IFF with a higher-growth, higher-margin core portfolio centered on Taste, Scent, and H&B.
Productivity is paying off in the core. In Q4, Taste Adjusted EBITDA surged 17% and H&B jumped 20% on comparable currency-neutral basis, significantly outpacing sales growth. Pricing and volume leverage are working.
🐻 Bear Case
The asset currently for sale is deteriorating rapidly. Q4 currency-neutral sales fell 4% and EBITDA dropped 11%. Erosion in fundamentals could complicate the sale process or pressure the valuation IFF can command.
Full-year Free Cash Flow came in at $256M, significantly missing the ~$500M target referenced in Q3. While one-time costs are a factor, cash conversion remains a weak spot relative to peers.
⚖️ Verdict: ⚪
Neutral/Positive. The underlying core business is healthy and accelerating, but the execution risk of selling a deteriorating Food Ingredients business—and the messy financials that accompany such a split—keeps us from being fully bullish immediately.
Key Themes
Aggressive Portfolio Transformation
IFF is radically simplifying. Having already divested Pharma Solutions and Nitrocellulose, the company formally announced the sale process for Food Ingredients. This follows a quarter where Food Ingredients was the only segment to shrink, dragging down consolidated results. The remaining 'New IFF' (Taste, Scent, H&B) profiles as a higher-growth specialty ingredients player.
Scent Margin Compression
While Scent sales grew 4% (CCN) in Q4, Adjusted EBITDA only grew 1%, implying margin compression. This contrasts sharply with the double-digit profit expansion in Taste and H&B. Unfavorable net pricing was cited as a headwind, signaling competitive pressure or input cost lag in this high-profile segment.
Deleveraging Target Achieved
Management delivered on its balance sheet repair. Net debt to credit-adjusted EBITDA finished 2025 at 2.6x, well within the target range. This financial flexibility removes the 'distressed' overhang from the stock and allows management to focus entirely on operational growth and the Food Ingredients exit.
GAAP Profitability Issues
Despite 'solid' adjusted numbers, IFF reported a GAAP Net Loss of $372M for FY25 and $412M loss before taxes. This was driven heavily by a $1.15B goodwill impairment earlier in the year and losses on assets held for sale ($115M). While 'adjusted' metrics look clean, the GAAP financials reflect the massive cost of restructuring and writedowns required to fix the portfolio.
H&B Turnaround Taking Hold
Health & Biosciences (H&B) is Accelerating. After struggling in prior quarters (flat in Q3), Q4 saw 5% sales growth and a massive 20% jump in Adjusted EBITDA. Volume growth and productivity gains are finally syncing up, validating the reinvestment strategy management touted throughout 2025.
Food Ingredients Drag
Reversing. Food Ingredients went from being a turnaround story in Q3 (EBITDA +24%) to a significant laggard in Q4 (EBITDA -11%). Volume declines and unfavorable net pricing hit the segment hard right as it goes up for sale, potentially complicating the divestiture valuation.
Other KPIs
Missed expectations. Management guided toward ~$500M in Q3, but landed at roughly half that amount. Operating Cash Flow ($850M) was weighed down by transaction costs and working capital, leaving little excess after $594M in CapEx.
Stable. Virtually flat vs 17.0% in Q4 2024. While productivity drove expansion in Taste and H&B, the collapse in Food Ingredients profitability dragged the consolidated average down.
Guidance
Stable. The range implies comparable currency neutral growth of 1% to 4%, consistent with 2025 levels. Foreign exchange is a tailwind (+1%), but divestitures will be a ~5% headwind.
Stable/Accelerating. The guidance implies 3% to 8% comparable currency neutral growth. Management expects profit to grow faster than sales, driven by productivity, even as divestitures remove absolute dollars from the P&L.
Key Questions
Food Ingredients Valuation Risk
With Food Ingredients EBITDA dropping 11% in Q4 and sales shrinking, how does this deterioration impact the valuation and timeline for the divestiture?
Scent Margin Pressure
Scent EBITDA growth (1%) lagged significantly behind sales growth (4%) in Q4 due to unfavorable net pricing. Is this a structural shift in pricing power for the segment, or a temporary mismatch with input costs?
Free Cash Flow Bridge
FY25 Free Cash Flow of $256M missed the ~$500M target discussed in Q3. What specific working capital or one-time items caused this shortfall in Q4, and does it impact the 2026 cash outlook?
H&B Sustainability
H&B posted impressive 20% EBITDA growth in Q4. Was there any one-time benefit (licensing, sale of IP) in the quarter, or is this the new run-rate margin profile for the segment?